What DSIP is, and why its name promises what its literature does not support

DSIP (delta sleep-inducing peptide) is a nonapeptide that the Schoenenberger–Monnier group in Basel isolated in 1977 from rabbit cerebral venous blood [1]. The name does not describe a demonstrated function: it describes the hypothesis it was searched for with.

The name is a hypothesis from 1977, not a finding

This is the first thing to understand about this compound, because it structures everything else. Since the early twentieth century it had been postulated that humoral factors induce sleep, and DSIP was one of only two that were purified and characterised [2]. It was named after the effect attributed to it. Half a century later, that effect remains unestablished.

What the reviews of the nineteen-eighties described

• Delta sleep in several species. The 1984 review describes induction mainly of delta sleep in rabbits, rats, mice and also in people, whereas in cats the more pronounced effect was on REM sleep [2].
• A U-shaped activity curve. Both for the amount given and for the infusion time, which means more was not more: a detail that complicates any simple reading of the results [2].
• Many effects outside sleep. Changes were described in electrophysiological activity, brain neurotransmitter levels, circadian and locomotor patterns and hormone levels [2].
• And a conclusion that has not aged. The 1986 update, two years later, closes by saying that the physiological functions of the peptide and its possible mechanism of action remain to be established [3].

The review that says it without hedging

In 2006, thirty years after the isolation, Kovalzon and Strekalova published a review titled «a still unresolved riddle» [1]. Three things from it:

• The link with sleep was never further characterised, in part — they write — because neither the DSIP gene, nor the protein, nor a possible receptor has been isolated. The hypothesis of DSIP as a sleep factor is, in their words, extremely poorly documented and still weak.
• Its natural occurrence and biological activity remain obscure. DSIP-like immunoreactivity is distributed in neurosecretory hypothalamic nuclei of various vertebrate species that are not particularly relevant to sleep regulation.
• And the point that is hardest to swallow: the authors note that certain artificial structural analogues of DSIP — but not DSIP itself — did show slow-wave-sleep-promoting activity in rabbits and rats in their own earlier studies. Their hypothesis is that a DSIP-like peptide, and not DSIP, lies behind what was observed.

What was measured in people, and what did not come out

There is literature in people, and it is worth reading in full rather than by its titles:

• It did not move growth hormone or prolactin. In eight healthy women with normal cycles, neither the baseline values, nor the circadian rhythm of both hormones, nor their response to arginine changed [4].
• And the result that contradicts the name. In 2009 a randomised controlled study in twenty-four patients tested it as an adjunct to isoflurane anaesthesia. It increased heart rate, decreased heart rate variability and, paradoxically — the word is the authors' —, reduced delta rhythm and raised the bispectral index, that is, it lightened the depth of anaesthesia. Their conclusion was that it probably reduced parasympathetic tone [5].

One study does not close a question, and this one was carried out under anaesthesia, which is not physiological sleep. But it is the most modern controlled work in people, and it runs in the opposite direction to what the product's name announces. Anyone buying it for what its name suggests should know this.

What does not exist

There is no marketing authorisation for DSIP at any agency. The Drugs@FDA register returns no match either for «DSIP» or for «delta sleep-inducing peptide», consulted on 16 September 2026. There is no approved indication, no posology and no validated route of administration for people.

This page describes published literature. It is not medical information, it does not describe a therapeutic use and it does not replace any healthcare professional.

What to look at when comparing suppliers

• Batch identity confirmation by mass spectrometry. It is a nonapeptide of known, small mass: the mass identifies it unambiguously.
• HPLC purity of the specific batch, with a certificate you can consult before buying.
• Be wary of anyone presenting the sleep effect as established. The reference review says the opposite, and anyone who has read it cannot claim otherwise.